PET in oncology: Will it replace the other modalities?

https://doi.org/10.1016/S0001-2998(97)80042-6Get rights and content

Medical imaging technology is rapidly expanding and the role of each modality is being redefined constantly. PET has been around since the early sixties and gained clinical acceptance in oncology only after an extreme number of scientific publications. Although PET has the unique ability to image biochemical processes in vivo, this ability is not fully used as a clinical imaging tool. In this overview, the role of PET in relation to other tumor imaging modalities will be discussed and the reported results in the literature will be reviewed. In predicting the future of PET, technical improvements of other imaging modalities need to be dealt with. The fundamental physical principles for image formation with computed tomography (CT), ultrasound (US), magnetic resonance imaging (MRI), photon-emission tomography (PET), and single photon emission CT (SPECT) will not change. The potential variety of radiopharmaceuticals which may be developed is unlimited, however, and this provides nuclear imaging techniques with a significant advantage and adaptive features for future biologic imaging. The current applications of PET in oncology have been in characterizing tumor lesions, differentiating recurrent disease from treatment effects, staging tumors, evaluating the extent of disease, and monitoring therapy. The future developments in medicine may use the unique capabilities of PET not only in diagnostic imaging but also in molecular medicine and genetics. The articles discussed in this review were selected from a literature search covering the last 3 years, and in which comparisons of PET with conventional imaging were addressed specifically. PET studies with the glucose analogue fluorine-18-labeled deoxyglucose (FDG) have shown the ability of detecting tumor foci in a variety of histological neoplasms such as thyroid cancer, breast cancer, lymphoma, lung cancer, head and neck carcinoma colorectal cancer, ovarian carcinoma, and musculoskeletal tumors. Also, the contribution of the whole body PET (WBPET) imaging technique in diagnosis will be discussed. In the current health care environment, a successful imaging technology must not only change medical management but also demonstrate that those changes improve patient outcome

References (85)

  • Di ChiroG et al.

    Glycolytic rate and histological grade of human cerebral gliomas: a study with 18F-fluorodeoxyglucose and positron emission tomography

  • Di ChiroG et al.

    Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence: A PET study

    Radiology

    (1987)
  • Di ChiroG

    Positron emission tomography using [18F]fluorodeoxyglucose in brain tumors — A powerful diagnostic and prognostic tool

    Invest Radiol

    (1987)
  • Di ChiroG et al.

    Cerebral necrosis after radiotherapy and/or intra-arterial chemotherapy for brain tumors: PET and neuropathologic studies

    AJR

    (1988)
  • WarburgO
  • WarburgO

    On the origins of cancer cells

    Science

    (1956)
  • IchiyaY et al.

    Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography

    J Nucl Med

    (1991)
  • BloomAD et al.

    Determination of malignancy of thyroid nodules with positron emission tomography

    Surgery

    (1993)
  • SissonJC et al.

    Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer: Implications for diagnosis and therapy

    J Clin Endocrinol Metab

    (1993)
  • AdlerLP et al.

    Positron emission tomography of thyroid masses

    Thyroid

    (1993)
  • WahlRL et al.

    Positron emission tomographic scanning of primary and metastatic breast with the radiolabeled glucose analogue 2-deoxy-2[18F]fluoro-D-glucose

    N Engl J Med

    (1991)
  • WahlRL et al.

    Primary and metastatic breast carcinoma: Initial clinical evaluation with PET with the radiolabeled glucose analogue-2-[F-18]-Fluoro-2-deoxy-D-glucose

    Radiology

    (1991)
  • TseNY et al.

    The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease

    Ann Surg

    (1992)
  • AdlerLP et al.

    Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET

    Radiology

    (1993)
  • NiewegOE et al.

    Positron emission tomography with fluorine-18-deoxy-glucose in the detection and staging of breast cancer

    Cancer

    (1993)
  • PaulR

    Comparison of fluorine-18-2 fluorodeoxyglucose and gallium 67 citrate imaging for detection of lymphoma

    J Nucl Med

    (1987)
  • OkadaJ et al.

    The use of FDG-PET in the detection and management of malignant lymphoma: Correlation of uptake with prognosis

    J Nucl Med

    (1991)
  • Leskinen-KallioS et al.

    Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: A PET study

    J Nucl Med

    (1991)
  • OkadaJ et al.

    Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity

    J Nucl Med

    (1992)
  • NewmanJS et al.

    Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: Correlation with CT

    Radiology

    (1994)
  • NolopKB et al.

    Glucose utilization in vivo by human pulmonary neoplasms

    Cancer

    (1987)
  • KubotaK et al.

    Differential diagnosis of lung tumor with positron emission tomography: A prospective study

    J Nucl Med

    (1990)
  • GuptaNC et al.

    Solitary pulmonary nodules: detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose

    Radiology

    (1992)
  • PatzEF et al.

    Focal pulmonary abnormalities: Evaluation with F-18 fluorodeoxyglucose PET scanning

    Radiology

    (1993)
  • HunterGJ et al.

    Lung tumor metastasis to breast detected by fluorine-18-fluorodeoxyglucose PET

    J Nucl Med

    (1993)
  • RegeSD et al.

    Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluorodeoxyglucose

    Cancer

    (1993)
  • SlosmanDO et al.

    Satellite PET and lung cancer: A prospective study in surgical patients

    Nuc Med Commun

    (1993)
  • HaberkornU et al.

    Glucose uptake, perfusion, and cell proliferation in head and neck tumors: Relation of positron emission tomography to flow cytometry

    J Nucl Med

    (1991)
  • BailetJW et al.

    Positron emission tomography: A new precise imaging modality for detection of primary head and neck tumors and assessment of cervical adenopathy

    Laryngoscope

    (1992)
  • RegeSD et al.

    Change induced by radiation therapy in FDG uptake in normal and malignant structures of the head and neck: quantitation with PET

    Radiology

    (1993)
  • ReisserC et al.

    The relevance of positron emission tomography for the diagnosis and treatment of head and neck tumors

    J Otolaryng

    (1993)
  • HaberkornU et al.

    Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy

    J Nucl Med

    (1993)
  • Cited by (0)

    View full text